Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful vigilantly but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my past few shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire employment interview which I came away with an inadequate viewpoint of the business.

Irony of irony, my poor impression of the business has grown steadily, however, the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and also associated intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and also the first new drug program endorsement ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and many therapies, it has this single treatment as well as a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple delivering presentations.

Might all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the really start of the interest of mine in this company. Judging by way of the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or maybe some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *